342 related articles for article (PubMed ID: 27806919)
1. 2-Year Outcomes of High Bleeding Risk Patients After Polymer-Free Drug-Coated Stents.
Garot P; Morice MC; Tresukosol D; Pocock SJ; Meredith IT; Abizaid A; Carrié D; Naber C; Iñiguez A; Talwar S; Menown IBA; Christiansen EH; Gregson J; Copt S; Hovasse T; Lurz P; Maillard L; Krackhardt F; Ong P; Byrne J; Redwood S; Windhövel U; Greene S; Stoll HP; Urban P;
J Am Coll Cardiol; 2017 Jan; 69(2):162-171. PubMed ID: 27806919
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Polymer-Free Biolimus A9-Coated Versus Bare-Metal Stents in Orally Anticoagulated Patients: 2-Year Results of the LEADERS FREE Oral Anticoagulation Substudy.
Carrié D; Menown I; Oldroyd K; Copt S; Talwar S; Maillard L; Morice MC; Teik LS; Lang I; Urban P
JACC Cardiovasc Interv; 2017 Aug; 10(16):1633-1642. PubMed ID: 28838473
[TBL] [Abstract][Full Text] [Related]
3. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
[TBL] [Abstract][Full Text] [Related]
4. Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk.
Urban P; Meredith IT; Abizaid A; Pocock SJ; Carrié D; Naber C; Lipiecki J; Richardt G; Iñiguez A; Brunel P; Valdes-Chavarri M; Garot P; Talwar S; Berland J; Abdellaoui M; Eberli F; Oldroyd K; Zambahari R; Gregson J; Greene S; Stoll HP; Morice MC;
N Engl J Med; 2015 Nov; 373(21):2038-47. PubMed ID: 26466021
[TBL] [Abstract][Full Text] [Related]
5. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
[TBL] [Abstract][Full Text] [Related]
6. Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk.
Windecker S; Latib A; Kedhi E; Kirtane AJ; Kandzari DE; Mehran R; Price MJ; Abizaid A; Simon DI; Worthley SG; Zaman A; Hudec M; Poliacikova P; Abdul Ghapar AKB; Selvaraj K; Petrov I; Mylotte D; Pinar E; Moreno R; Fabbiocchi F; Pasupati S; Kim HS; Aminian A; Tie C; Wlodarczak A; Hur SH; Marx SO; Jankovic I; Brar S; Bousquette L; Liu M; Stone GW;
N Engl J Med; 2020 Mar; 382(13):1208-1218. PubMed ID: 32050061
[TBL] [Abstract][Full Text] [Related]
7. The EXAMINATION trial (Everolimus-Eluting Stents Versus Bare-Metal Stents in ST-Segment Elevation Myocardial Infarction): 2-year results from a multicenter randomized controlled trial.
Sabaté M; Brugaletta S; Cequier A; Iñiguez A; Serra A; Hernádez-Antolín R; Mainar V; Valgimigli M; Tespili M; den Heijer P; Bethencourt A; Vázquez N; Backx B; Serruys PW
JACC Cardiovasc Interv; 2014 Jan; 7(1):64-71. PubMed ID: 24332423
[TBL] [Abstract][Full Text] [Related]
8. Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?: A Pre-Specified Analysis From the ZEUS Trial.
Ariotti S; Adamo M; Costa F; Patialiakas A; Briguori C; Thury A; Colangelo S; Campo G; Tebaldi M; Ungi I; Tondi S; Roffi M; Menozzi A; de Cesare N; Garbo R; Meliga E; Testa L; Gabriel HM; Ferlini M; Vranckx P; Valgimigli M;
JACC Cardiovasc Interv; 2016 Mar; 9(5):426-36. PubMed ID: 26965932
[TBL] [Abstract][Full Text] [Related]
9. Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) and COMFORTABLE-AMI (Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) trials.
Sabaté M; Räber L; Heg D; Brugaletta S; Kelbaek H; Cequier A; Ostojic M; Iñiguez A; Tüller D; Serra A; Baumbach A; von Birgelen C; Hernandez-Antolin R; Roffi M; Mainar V; Valgimigli M; Serruys PW; Jüni P; Windecker S
JACC Cardiovasc Interv; 2014 Jan; 7(1):55-63. PubMed ID: 24332419
[TBL] [Abstract][Full Text] [Related]
10. Rationale and design of the LEADERS FREE trial: A randomized double-blind comparison of the BioFreedom drug-coated stent vs the Gazelle bare metal stent in patients at high bleeding risk using a short (1 month) course of dual antiplatelet therapy.
Urban P; Abizaid A; Chevalier B; Greene S; Meredith I; Morice MC; Pocock S
Am Heart J; 2013 May; 165(5):704-9. PubMed ID: 23622906
[TBL] [Abstract][Full Text] [Related]
11. Prediction of 1-year clinical outcomes using the SYNTAX score in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a substudy of the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) trials.
Garg S; Sarno G; Serruys PW; Rodriguez AE; Bolognese L; Anselmi M; De Cesare N; Colangelo S; Moreno R; Gambetti S; Monti M; Bristot L; Bressers M; Garcia-Garcia HM; Parrinello G; Campo G; Valgimigli M;
JACC Cardiovasc Interv; 2011 Jan; 4(1):66-75. PubMed ID: 21251631
[TBL] [Abstract][Full Text] [Related]
12. Long-Term outcome of drug-eluting stents compared with bare metal stents in ST-segment elevation myocardial infarction: results of the paclitaxel- or sirolimus-eluting stent versus bare metal stent in Primary Angioplasty (PASEO) Randomized Trial.
Di Lorenzo E; Sauro R; Varricchio A; Carbone G; Cortese G; Capasso M; Lanzillo T; Manganelli F; Mariello C; Siano F; Pagliuca MR; Stanco G; Rosato G; De Luca G
Circulation; 2009 Sep; 120(11):964-72. PubMed ID: 19720939
[TBL] [Abstract][Full Text] [Related]
13. 2-year clinical follow-up from the randomized comparison of biolimus-eluting stents with biodegradable polymer and sirolimus-eluting stents with durable polymer in routine clinical practice.
Klauss V; Serruys PW; Pilgrim T; Buszman P; Linke A; Ischinger T; Eberli F; Corti R; Wijns W; Morice MC; di Mario C; van Geuns RJ; van Es GA; Kalesan B; Wenaweser P; Jüni P; Windecker S
JACC Cardiovasc Interv; 2011 Aug; 4(8):887-95. PubMed ID: 21851904
[TBL] [Abstract][Full Text] [Related]
14. Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet Therapy.
Kereiakes DJ; Yeh RW; Massaro JM; Driscoll-Shempp P; Cutlip DE; Steg PG; Gershlick AH; Darius H; Meredith IT; Ormiston J; Tanguay JF; Windecker S; Garratt KN; Kandzari DE; Lee DP; Simon DI; Iancu AC; Trebacz J; Mauri L;
JACC Cardiovasc Interv; 2015 Oct; 8(12):1552-62. PubMed ID: 26493248
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of 6-month versus 12-month dual antiplatelet therapy in patients after implantation of multiple biodegradable polymer-coated sirolimus-eluting coronary stents: Insight from the I-LOVE-IT 2 trial.
Qi J; Li Y; Li J; Jing Q; Xu K; Gao C; Ma L; Zhang Z; Xu B; Han Y
Catheter Cardiovasc Interv; 2017 Mar; 89(S1):555-564. PubMed ID: 28318138
[TBL] [Abstract][Full Text] [Related]
16. Biolimus-A9 polymer-free coated stent in high bleeding risk patients with acute coronary syndrome: a Leaders Free ACS sub-study.
Naber CK; Urban P; Ong PJ; Valdes-Chavarri M; Abizaid AA; Pocock SJ; Fabbiocchi F; Dubois C; Copt S; Greene S; Morice MC;
Eur Heart J; 2017 Apr; 38(13):961-969. PubMed ID: 27190095
[TBL] [Abstract][Full Text] [Related]
17. Comparison of drug-eluting and bare-metal stents for primary percutaneous coronary intervention with or without abciximab in ST-segment elevation myocardial infarction: DEBATER: the Eindhoven reperfusion study.
Wijnbergen I; Helmes H; Tijssen J; Brueren G; Peels K; van Dantzig JM; Van' t Veer M; Koolen JJ; Pijls NH; Michels R
JACC Cardiovasc Interv; 2012 Mar; 5(3):313-22. PubMed ID: 22440498
[TBL] [Abstract][Full Text] [Related]
18. Polymer-free Biolimus A9-coated stents in the treatment of de novo coronary lesions with short DAPT: 9-month angiographic and clinical follow-up of the prospective, multicenter BioFreedom USA clinical trial.
Waksman R; Piegari GN; Kabour A; Cannon L; Wang J; Adams G; Solankhi N; Smeglin A; Kereiakes DJ; Leiboff R; Spad MA; Torguson R; Chandra N; Bastian R; DeGroot J; Kayo MW; Stoll HP; Garcia-Garcia HM
Cardiovasc Revasc Med; 2017; 18(7):475-481. PubMed ID: 28923692
[TBL] [Abstract][Full Text] [Related]
19. Randomized comparison of everolimus-eluting stents and sirolimus-eluting stents in patients with ST elevation myocardial infarction: RACES-MI trial.
Di Lorenzo E; Sauro R; Varricchio A; Capasso M; Lanzillo T; Manganelli F; Carbone G; Lanni F; Pagliuca MR; Stanco G; Rosato G; Suryapranata H; De Luca G
JACC Cardiovasc Interv; 2014 Aug; 7(8):849-56. PubMed ID: 25147029
[TBL] [Abstract][Full Text] [Related]
20. Global Approach to High Bleeding Risk Patients With Polymer-Free Drug-Coated Coronary Stents: The LF II Study.
Krucoff MW; Urban P; Tanguay JF; McAndrew T; Zhang Y; Rao SV; Morice MC; Price MJ; Cohen DJ; Abdel-Wahab M; Mehta SR; Faurie B; McLaurin B; Diaz C; Stoll HP; Pocock S; Leon MB
Circ Cardiovasc Interv; 2020 Apr; 13(4):e008603. PubMed ID: 32279567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
